EMEA-001186-PIP01-11-M03
Key facts
Invented name |
Iclusig
|
Active substance |
Ponatinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0122/2022
|
PIP number |
EMEA-001186-PIP01-11-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Incyte Biosciences Distribution B.V.
E-mail: globalmedinfo@incyte.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|